218 related articles for article (PubMed ID: 16965187)
21. The neurobiology of cognition in schizophrenia.
Tamminga CA
J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
[TBL] [Abstract][Full Text] [Related]
22. [Approaches to the development of the Japanese academic version of the MATRICS Consensus Cognitive Battery].
Sato T; Sora I
Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):241-4. PubMed ID: 22256613
[TBL] [Abstract][Full Text] [Related]
23. The MATRICS consensus cognitive battery: what we know 6 years later.
Green MF; Harris JG; Nuechterlein KH
Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
[No Abstract] [Full Text] [Related]
24. The NIMH-MATRICS consensus statement on negative symptoms.
Kirkpatrick B; Fenton WS; Carpenter WT; Marder SR
Schizophr Bull; 2006 Apr; 32(2):214-9. PubMed ID: 16481659
[No Abstract] [Full Text] [Related]
25. Treatment of cognitive deficits in schizophrenia.
Bowie CR; Harvey PD
Curr Opin Investig Drugs; 2006 Jul; 7(7):608-13. PubMed ID: 16869112
[TBL] [Abstract][Full Text] [Related]
26. Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference.
Green MF; Olivier B; Crawley JN; Penn DL; Silverstein S
Schizophr Bull; 2005 Oct; 31(4):882-7. PubMed ID: 16135561
[TBL] [Abstract][Full Text] [Related]
27. New paradigms for treatment development.
Stover EL; Brady L; Marder SR
Schizophr Bull; 2007 Sep; 33(5):1093-9. PubMed ID: 17673495
[TBL] [Abstract][Full Text] [Related]
28. Psychotherapeutic Medications Development Program (PMDP).
Haigler HJ; Cott JM; Rudorfer MV; Schoenfeld RE; Potter WZ; Vitiello B; Everist HD
Psychopharmacol Bull; 1993; 29(2):241-7. PubMed ID: 8290672
[TBL] [Abstract][Full Text] [Related]
29. Medicine. What are the right targets for psychopharmacology?
Hyman SE; Fenton WS
Science; 2003 Jan; 299(5605):350-1. PubMed ID: 12532001
[No Abstract] [Full Text] [Related]
30. [Functional outcome in schizophrenia: relation to the MATRICS consensus cognitive battery].
Sumiyoshi C
Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):251-7. PubMed ID: 22256615
[TBL] [Abstract][Full Text] [Related]
31. [Cognitive remediation and cognitive assistive technologies in schizophrenia].
Sablier J; Stip E; Franck N
Encephale; 2009 Apr; 35(2):160-7. PubMed ID: 19393385
[TBL] [Abstract][Full Text] [Related]
32. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia.
Marder SR
Dialogues Clin Neurosci; 2006; 8(1):109-13. PubMed ID: 16640121
[TBL] [Abstract][Full Text] [Related]
33. [Cognitive deficits in schizophrenia and other psychotic disorders].
Fagerlund B; Glenthøj BY
Ugeskr Laeger; 2008 Nov; 170(46):3770-2. PubMed ID: 19014728
[TBL] [Abstract][Full Text] [Related]
34. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
[TBL] [Abstract][Full Text] [Related]
35. The neurobiology of cognition in schizophrenia.
Tamminga CA
J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
[TBL] [Abstract][Full Text] [Related]
36. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
Buchanan RW; Keefe RS; Umbricht D; Green MF; Laughren T; Marder SR
Schizophr Bull; 2011 Nov; 37(6):1209-17. PubMed ID: 20410237
[TBL] [Abstract][Full Text] [Related]
37. Developing an outcomes-oriented approach for the treatment of schizophrenia.
Lehman AF
J Clin Psychiatry; 1999; 60 Suppl 19():30-5; discussion 36-7. PubMed ID: 10507278
[TBL] [Abstract][Full Text] [Related]
38. Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers.
Tcheremissine OV; Castro MA; Gardner DR
Expert Opin Investig Drugs; 2012 Jan; 21(1):7-14. PubMed ID: 22059602
[TBL] [Abstract][Full Text] [Related]
39. [The cognitive deficit in schizophrenia].
Krivoy A; Fischel T; Weizman A
Harefuah; 2012 May; 151(5):277-80, 319. PubMed ID: 22844731
[TBL] [Abstract][Full Text] [Related]
40. [Learning potential and cognitive remediation in schizophrenia].
Raffard S; Gely-Nargeot MC; Capdevielle D; Bayard S; Boulenger JP
Encephale; 2009 Sep; 35(4):353-60. PubMed ID: 19748372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
